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ABSTRACT
In this study, we examined associations between pancreatic cancer that met 
the Yonsei criteria (YC) and classifications from the 8th edition of the American 
Joint Committee on Cancer (AJCC) staging system. Clinicopathological and survival 
data were collected from132 patients who underwent distal pancreatectomy for 
left-sided pancreatic ductal adenocarcinoma between January 2000 and December 
2015, and the utility of the YC for selecting treatment and predicting survival was 
evaluated using the 8th AJCC staging manual. Of the 102 patients who ultimately 
qualified for the study, 45 patients were reclassified as stage I based on the 8th 
AJCC cancer staging system. Disease-free survival and disease-specific survival 
periods were longer in stage I patients who met the YC than in those who did not. 
Clinicopathological characteristics did not differ between stage I patients who did 
and did not meet the YC. These results suggest that meeting the YC criteria may 
be a clinical indicator that left-sided pancreatic cancer patients who are candidates 
for resection have early-stage disease according to the 8th edition of the AJCC 
staging manual.
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INTRODUCTION
Laparoscopic surgery has been accepted as the 
gold standard treatment in many oncologic fields [1–3]. 
Specifically, laparoscopic distal pancreatectomy is used 
for the treatment of benign and low-grade malignant 
pancreatic tumors. Several recent studies suggest that 
laparoscopic radical pancreatectomy could be also feasible 
and effective in treating pancreatic cancer [4–8]. However, 
the use of minimally-invasive radical pancreatectomy is 
still controversial because most patients are diagnosed 
with advanced-stage cancer that requires challenging 
surgical techniques; furthermore, this technique has not 
yet been evaluated in a randomized, controlled study.
Since 2007, our group has studied whether-minimally 
invasive pancreatectomy might be a safe and effective 
treatment for left-sided pancreatic cancer. Our results 
indicate that bloodless and margin-negative resection is 
crucial for treating pancreatic cancer arising from pancreatic 
body and tail lesions [9]. Based on this observation, we 
developed the following set of tumor conditions, termed 
Yonsei criteria (YC) [10, 11], to determine whether 
treatment with laparoscopic radical distal pancreatectomy 
is indicated: 1) tumor confined to the pancreas, 2) intact 
fascia layer between the distal pancreas and the left 
adrenal gland and kidney, and 3) tumor located more than 
1–2 cm from the celiac axis. YC can be evaluated based 
on preoperative CT scans. For tumors that meet all three 
YC, currently available minimally-invasive techniques 
are highly safe and effective for achieving bloodless and 
margin-negative resection during the treatment of left-sided 
pancreatic cancer. In support of this hypothesis, our recent 
data demonstrate that long-term oncologic outcomes of 
minimally invasive radical pancreatectomy for left-sided 
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pancreatic cancer that meets the YC were more favorable 
compared to those obtained with an open approach [12, 13]. 
Moreover, although surgical approach (minimally-invasive 
vs. open) is less predictive of oncologic outcome, YC 
strongly predicted long-term oncologic outcomes after 
radical pancreatectomy for left-sided pancreatic cancer. 
This suggests that YC is not only a potential indicator for 
minimally invasive radical pancreatectomy for treating 
left-sided pancreatic cancer, but may also represent some 
aspects of distal pancreatic cancer tumor biology [13].
Recently, the American Joint Committee on Cancer 
(AJCC) developed the 8th version of their cancer staging 
system for pancreatic cancer [14]. Unlike the 7th AJCC 
system [15], the new version states that T-stage is determined 
based on tumor size (T1: maximum tumor diameter ≤ 2 cm, 
T2: maximum tumor diameter >2 cm and ≤ 4 cm, T3: 
maximum tumor diameter >4 cm, and T4: unresectable 
primary tumor involving the celiac axis or the superior 
mesenteric artery), and N-stage has been recategorized 
based on the number of metastatic lymph nodes (N0: no 
regional lymph node metastasis, N1: metastasis in 1–3 
regional lymph nodes, and N2: metastasis in ≥ 4 regional 
lymph nodes). According to the 7th AJCC cancer staging 
system, most left-sided pancreatic cancer that met the YC 
were categorized as T3-pancreatic cancer, and it was unclear 
why oncologic outcomes for pancreatic cancer that met the 
YC were superior to those that did not [12]. 
In this study, we examined associations between 
YC status and the 8th version of the AJCC cancer staging 
system categorizations to determine whether clinical YC 
classification is related to aspects of tumor biology in left-
sided pancreatic cancer. 
RESULTS
Oncologic outcomes for resected left-sided 
pancreatic cancer depending Yonsei criteria status
Among the 102 qualifying patients who 
underwent potentially curative resection of left-sided 
pancreatic cancer, 55 (53.9%) met the Yonsei criteria 
(YC) based on preoperative CT scans. Patients who 
did not meet the YC were much more likely to undergo 
combined organ resection (5/50 vs. 19/28, p < 0.001). 
Preoperative CT-based YC also strongly predicted 
long-term oncologic outcome. Mean disease-free (56.2 
months [95% CI: 39.5–72.9] vs. 27.6 months [95% 
CI:12.8–42.3], p < 0.001, Figure 1A) and disease-
specific survival (63.8 months [95% CI: 46.9–80.6] 
vs. 31.9 months [95% CI: 15.1–48.8], p = 0.001, 
Figure 1B) were longer in patients who met the YC 
than in those who did not.
Associations between Yonsei criteria and AJCC 
cancer staging systems
According to 7th AJCC staging system, 94 patients 
(92.2%) were classified as T3. Additionally, most patients 
who met the YC were diagnosed with T3 pancreatic 
cancer (53 out of 57, 92.9%, Table 1). YC status was not 
correlated with T-stage from the 7th AJCC staging system 
(p = 0.425). However, YC was strongly associated with 
small-sized pancreatic cancer as described by the 8th 
AJCC cancer staging system (p = 0.019, chi-square, 
linear-to-linear association, Table 1). Tumor sizes were 
smaller in patients who met the YC, of whom 12 (21.1%) 
had pancreatic cancer tumors smaller than 2 cm, than 
in those who did not (2.9 ± 1.4 cm vs. 3.7 ± 1.7 cm, 
p = 0.012).
In contrast, YC was strongly associated with 
N-stage from 7th AJCC cancer staging system 
(p = 0.011). YC was also associated with small 
numbers of metastatic lymph nodes according 
to 8th AJCC cancer staging system (p = 0.015, 
chi-square, linear-to-linear association, Table 2); 
patients who met the YC had fewer lymph node 
metastases than those who did not (0.8 ± 1.5 vs. 
2.0 ± 3.1, p = 0.037).
Figure 1: Oncologic outcomes in patients who do and do not meet the YC. (A) Disease-free survival, (B) Disease-specific 
survival.
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Prognosis prediction in resected left-sided 
pancreatic cancer using the 8th AJCC cancer 
staging system
As described above, most patients with resected left-
sided pancreatic cancer were diagnosed with T3 disease 
according to 7th AJCC cancer staging system. It was 
therefore difficult to stratify the patient group because 
most had stage II cancer (Figure 2A and Figure 3A). 
However, prognostic differences became clear when the 
patients were classified according to 8th AJCC cancer 
staging system (Figure 2B, and Figure 3B); the 5-year 
disease-specific survival rate for stage I left-sided 
pancreatic cancer was 52.3%, with a mean survival time 
of 76 months [95% CI: 52.2–100.7].  
Stage-migration of patients meeting Yonsei 
criteria in the 8th AJCC cancer staging system
 Unlike the 7th AJCC cancer staging system, which 
classified most patients with resected left-sided pancreatic 
cancer who met the YC as stage II (52 out of 55 patients, 
Table 1: T-stage distribution of resected-left sided pancreatic cancer
7th AJCC staging system
p-value
T1 T2 T3
Within YC 0 4 53
Out of YC 2 2 41 0.425
8th AJCC staging system
p-value
T1 T2 T3
Within YC 12 39 8
Out of YC 8 20 17 0.019
Table 2: N-stage distribution of resected-left sided pancreatic cancer
7th AJCC staging system
p-value
N0 N1
Within YC 36 21
Out of YC 17 28 0.011
8th AJCC staging system
p-value
N0 N1 N2
Within YC 36 16 5
Out of YC 17 20 8 0.015
Figure 2: Disease-free survival for the two cancer staging systems. (A) 7th AJCC cancer staging system, (B) 8th AJCC cancer 
staging system.
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94.5%), 30 patients who met the YC (54.5%) were 
reclassified as stage I according to 8th AJCC cancer staging 
system; these patients comprised 66.7% of all patients with 
stage I resected left-sided pancreatic cancers (32 out of 
45 patients). In addition, 87.1% of patients with stage IIA 
resected left-sided pancreatic cancer according to the 7th 
AJCC cancer staging system who met the YC (27 out of 
31 patients) were reclassified as having stage I pancreatic 
cancer by the 8th AJCC cancer staging system (Figure 4).
Yonsei criteria reflect clinically detectable early 
pancreatic cancer
Of the 102 patients who underwent potentially 
curative resection for left-sided pancreatic cancer, 45 
patients (44.1%) were reclassified as having stage I 
disease based on the 8th AJCC cancer staging system. 
Interestingly, oncologic outcome for stage I pancreatic 
cancer differed depending on YC status. Mean disease-
free (68.4 months [95% CI: 45.6–91.10 vs. 43.1 months 
[95% CI: 12.0–74.1], p = 0.035, Figure 5A) and disease-
specific survival (78.8 months [95% CI: 55.8–101.9] vs. 
50.7 months [95% CI: 18.5–82.9], p = 0.019, Figure 5B) 
were longer in stage I pancreatic cancer patients who met 
the YC than in those who did not. Clinicopathological 
characteristics did not differ between stage I pancreatic 
cancer patients who did and did not meet the YC (Table 3).
DISCUSSION
Based on our surgical experience with distal 
pancreatic cancer [9], we recently developed the YC 
as a potential indicator of the safety and efficacy of 
minimally-invasive pancreatectomy for left-sided 
pancreatic cancer [10, 11, 16]. We also demonstrated that, 
regardless of whether minimally-invasive surgery or open 
pancreatectomy was performed, left-sided pancreatic 
cancer patients who met the YC had more favorable long-
term oncologic outcomes; propensity score matching 
analysis confirmed this result [12, 13]. The results of this 
study indicate that YC status may also reflect underlying 
tumor biology in pancreatic cancer patients when the 8th 
AJCC cancer staging system is used. YC status, which is 
based on preoperative CT scans, is thus clinical predictive 
factor of long-term survival outcomes for resected left-
sided pancreatic cancer; most predictive factors in this 
Figure 3: Disease-specific survival for the two cancer staging systems. (A) 7th AJCC cancer staging system, (B) 8th AJCC 
cancer staging system.
Figure 4: Stage-migration of left-sided pancreatic cancer that met the YC.
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disease are pathology-associated characteristics, such as 
lymph node metastasis [17], perineural invasion [18, 19], 
cell differentiation [20], and margin status [21], among 
others. 
Here, we found that YC status was closely 
associated with T-stage in pancreatic cancers when 
the new tumor size guidelines were used (Table 1). 
Less extensive lymph node metastasis, as classified 
according to the 8th edition of the AJCC cancer 
staging manual, was also associated with cancers 
that met the YC (Table 2). Furthermore, 30 patients 
who met the YC (54.5%) were reclassified as having 
stage I pancreatic cancer (Figure 4), and 30 stage I 
pancreatic cancer patients (66.7%) met the YC, 
when the 8th AJCC cancer staging system was used. 
Although clinicopathological characteristics did not 
Table 3: Clinico-pathological characteristics between stage I pancreatic cancer within Yonsei criteria and that out of 
Yonsei criteria
8th AJCC-stage I pancreatic cancer
p-value
Within YC (N = 30) Out of YC ( N = 15)
Gender (Male/Female) 18/12 8/7 0.670
Age, years 64.2 ± 7.5 64.3 ± 10.5 0.990
Symptoms (No/Yes) 15/15 3/12 0.105












LVI 24/6 11/4 0.710
PNI 12/18 8/7 0.396
Retrieved LNs 15.0 ± 10.6 11.2 ± 9.1 0.220
R-status (R0/R1) 27/3 15/0 0.540
Postoperative complication (No/Yes) 21/9 6/9 0.105
POPF (No/Yes) 24/6 11/4 0.710
Postoperative adjuvant CTx (No/Yes) 7/22 5/10 0.516
Figure 5: Oncologic outcomes for patients with stage I pancreatic cancer according to AJCC 8th staging system who 
do or do not meet the YC. (A) Disease-free survival, (B) Disease-specific survival.
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differ between stage I patients who did and did not 
meet the YC (Table 3), survival outcomes of stage 
I-distal pancreatic cancer patients differed depending 
on YC status (Figure 5). These findings suggest that 
YC itself may be a valuable clinical measure for 
predicting oncologic outcomes in patients with left-
sided pancreatic cancer. As Rooij et al. [4] point out, 
evidence on the oncological feasibility of laparoscopic 
distal pancreatectomy is lacking; they therefore 
developed a decision-aid algorithm and proposed that 
small tumors and pT1/pT2 pancreatic cancer be treated 
by laparoscopic distal pancreatectomy. We previously 
developed YC to further assist in identifying patients 
who are eligible for a laparoscopic approach. 
According to the present results, most pancreatic 
cancer tumors that met the YC were relatively small 
and were classified as T1 or T2 pancreatic cancer 
using the 8th AJCC cancer staging system (Table 1). 
YC status may therefore be a reasonable indicator for 
the use of minimally-invasive radical pancreatectomy 
in left-sided pancreatic cancer and may be predictive 
of long-term survival. Additional studies should be 
performed in larger patient groups to confirm these 
results. Coincidentally, a recent ongoing randomized 
control trial has already identified YC as an inclusion 
criteria in diagnosing left-sided pancreatic cancer [22].
Several limitations of this study should be 
considered when interpreting the results. First, this 
study is retrospective. Second, the number of patients 
who met the YC is relatively small. Third, preoperative 
CT-based YC determinations may be subjective, and 
inter-observer biases might exist. Modifications to 
the YC might improve their ability to preoperatively 
define tumor characteristics more objectively, and thus 
more accurately represent tumor biology, in left-sided 
pancreatic cancer. 
In summary, resected left-sided pancreatic cancer 
that meets the YC is a clinical marker of early (stage I) 
pancreatic cancer as classified by the 8th edition of AJCC 
cancer staging manual and is indicative of favorable tumor 
biology. In particular, stage I pancreatic cancer patients 
who meet the YC might be expected to have better long-
term survival. This study provides a basis for additional 
investigations of left-sided pancreatic cancer patient 
subgroups that might benefit from minimally-invasive 
radical pancreatectomy.
MATERIALS AND METHODS
Between January 2000 and December 2015, 132 
patients received distal pancreatectomies to treat left-
side pancreatic ductal adenocarcinoma. Among them, 27 
patients who underwent resection following neoadjuvant 
chemotherapy with or without radiation and 3 patients 
who underwent palliative distal pancreatectomies were 
excluded. The medical records of the remaining 102 
patients were retrospectively reviewed. Patients were 
categorized according to the YC [10, 11, 16], and the 
following clinicopathological data were collected: age, 
sex, presenting symptoms, serum CA 19–9, combined 
resection, adjuvant treatment, postoperative complication, 
cell differentiation, tumor size, T stage, N stage, number 
of retrieved lymph nodes (LN), number of positive LN, 
lymph node ratio, lymphovascular invasion, perineural 
invasion, and adjusted organ invasion. Survival data 
were obtained in institutional follow-ups for analysis of 
oncologic outcomes. The new 8th AJCC cancer staging 
manual [14] was used to classify patients and validate the 
YC. Disease-free survival and disease-specific overall 
survival periods were calculated from the date of operation 
to either the date recurrence was diagnosed or to the date 
of cancer-related death. 
Statistical analyses were performed in IBM SPSS 
Statistics version 22. Continuous variables are represented 
as means ± standard deviations or medians with ranges, 
and categorical variables as percentages or frequencies. 
Student’s t-tests were applied for comparing continuous 
variables, and Fisher’s exact tests or Chi-squared tests 
were used for comparing categorical data. The Kaplan–
Meier method was used for analysis of disease-free and 
overall survival. P < 0.05 was considered statistically 
significant. This study is a retrospective cohort study 
conducted at a single institution and was approved by the 
institutional review board. 
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